reported the relationship between PFN1 and HT in the human population.
Recently, the effects of antihypertensive drugs losartan, amlodipine, and atenolol on the vascular hypertrophy-associated HT were assessed by treating the profilin1 transgenic mice for 4 weeks. The results showed that the BP of treated mice was lowered and the degree of vascular hypertrophy was reduced. 19 To better understand the role of profilin1 in the development of HT, we evaluated the association of PFN1 with HT in a case-control study and an average 5.01 years follow-up study in the Han Chinese population.
METHODS

Study Population
A case-control study was conducted in a rural population using the epidemiological cluster sampling approach in Yixing, Jiangsu province, China. 15 A total of 2,012 hypertensive cases and 2,210 age-(5 years) and sex-matched normotensives were recruited (May-October, 2009). To reduce the recall bias, the population data were checked and sorted again in the September, 2016. HT was defined as mean systolic BP ≥140 mm Hg and/or mean diastolic BP ≥90 mm Hg, or currently taking any antihypertensive medication.
Excluding 94 elder controls in the case-control study, the follow-up study was carried out among 2,116 healthy controls. The incidence of HT was set as the endpoint of follow-up. The follow-up population survey was mostly conducted in 2014 and 2015, and the rest was completed in 2016. Face-to-face interview and telephone interview were mainly performed to ascertain disease status and vital information. Registered disease records from the local public health department were reviewed and verified by a study-wide endpoint assessment committee at Yixing Hospital. The study protocol was approved by the Research Ethics Committee of Nanjing Medical University. Written informed consent was obtained from all participants prior to interview.
Data collection
Demographic data including age, gender, nation, education, occupation, status of smoking and drinking, and a history of current use of antihypertensive medications were recorded through the interviewer-administered questionnaires. Meanwhile, all participants received the physical examinations including measurements of weight, height, and BP. BP was measured 3 times after 5 minutes of rest when the subjects were in the sitting position in accordance to the standard procedures and recommendations. 20 Additionally, participants were advised to avoid alcohol, cigarette smoking, coffee, tea, and exercise for at least 30 minutes before their BP measurements. Peripheral venous blood was sampled after 10 hours of an overnight fasting to measure the level of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), and glucose (GLU).
Selection of polymorphisms
PFN1 (Gene ID: 5216) is mapped on chromosome 17 p13.2 and spans 3, 410 bp with 3 exons. The single nucleotide polymorphisms (SNPs) were selected to cover PFN1 gene starting from the upstream 5 kb to the downstream 2 kb according to the database of Chinese Hans population of Beijing, the human reference genome (http://phase3browser.1000genomes.org/, last accessed 16 May 2017). ENO3 is located in a 4 kb upstream region to PFN1 and thus the SNPs at ENO3 are also included in this study. All tagSNPs were selected using Haploview software (version 4.2) with the criteria of minor allele frequency ≥0.05 and r 2 ≥0.8 according to the linkage disequilibrium values (Supplementary Figure 1) . Furthermore, a functional candidate strategy was applied to search functional SNPs on the website of selection tool for SNPs (SNPINFO, https://snpinfo. niehs.nih.gov/, last accessed 14 May 2017). Finally, 2 tagSNPs rs238243 and rs2233656 at PFN1 and 2 tagSNPs rs238238 and rs238239 at ENO3 were selected. The biological information analysis for regions, alleles, minor allele frequencies, predicted functions, and Regulome DB score of the 4 SNPs were shown in Supplementary Table S1 .
Blood sampling and SNP genotyping
Blood samples for genotyping were deposited in the ethylenediamine tetraacetic acid containing receptacles. The Genomic DNA was extracted using standard phenolchloroform method. 21 5′-Nuclease TaqMan assay were used for genotyping in 384-well plates on ABI PRISM 7900HT Sequence Detection system (Applied BioSystems, Foster City, CA). The primers and probes of TaqMan assays were designed using Primer Express Oligo Design software v2.0 (ABI PRISM) and available upon request as TaqMan PreDesigned SNP Genotyping Assays. Polymerase chain reaction (PCR) reactions were performed in a 5 µl reaction mixture including 10 ng DNA, 2.4 µl 2 × TaqMan Universal PCR Master Mix. Identification of Individual genotypes was performed by Sequence Detection System 2.1 software (95% autocaller confidence level). The PCR conditions were 50 °C for 2 minutes, 95 °C for 10 minutes, 95 °C for 15 seconds and then 60 °C for 1 minute, and 45 cycles of real-time PCR were performed. The successful call rates of 4 SNPs are over 99%.
Blood plasma profilin1 detecting
Profilin1 in blood plasma was measured in a randomized sample including 90 HT cases without taking any antihypertensive drugs and 115 healthy controls using the Human Profilin1 ELISA KIT (Catalogue No. CSB-E16491h, China) from CUSABIO Laboratories. Blood plasma was collected using heparin as an anticoagulant, and centrifuged for 15 minutes at 1000×g, 4 °C within 30 minutes. Antibody specific for profilin1 has been precoated a microplate. One hundred microliter standards and samples were pipetted into the wells and any profilin1 present was bound by the immobilized antibody. After removing any unbound substances, a biotinconjugated antibody specific for profilin1 was added to the wells. After aspirating and washing 3 times, 100 µl avidin conjugated Horseradish Peroxidase (HRP) was added to the wells.
Following a wash to remove any unbound avidin-enzyme reagent, 90 µl TMB substrate solution was added to the wells and color develops in proportion to the amount of profilin1 bound in the initial step. Finally, 50 µl stop solution was added to each well and read at 450 nm within 5 minutes. The color development was stopped and the intensity of the color was measured.
Statistical analysis
Quantitative variables with normal distribution were expressed as mean ± SD, and the differences between cases and controls were assessed with unpaired Student's t-test. Profilin1 concentration with non-Gaussian distribution was expressed as median (interquartile range), and the differences of profilin1 between HT cases and controls as well as among genotypes were assessed with Mann-Whitney U test and Jonckheere-Terpstra Test, respectively. Among the control subjects, the genotype frequencies were tested with Fisher exact chi-square (χ 2 ) test for Hardy-Weinberg equilibrium. The associations between the SNPs and HT in casecontrol study were evaluated using logistic regression after adjusting for potential confounding factors, and the odds ratio and 95% confidence interval were calculated. General linear model was applied to compare BP levels between genotypes. Person years of follow-up were calculated and hazard ratio and 95% confidence interval of incident HT were estimated using time-dependent Cox proportional hazards regression model. Two-tailed P value <0.05 was defined to be statistically significant. All the statistical analysis above was performed using SPSS for Windows version 15.0 (SPSS, Chicago, IL). Furthermore, to test the associations of statistical haplotypes with HT, the haplotype was constructed using HAPSTAT 3.0 software (http://dlin.web.unc.edu/software/ hapstat/, last accessed 16 May 2017) and the covariates were adjusted as well.
The power of this case-control study was calculated using the Power and Sample Size Calculation software (Dupont WD, Plummer WD: http://biostat.mc.vanderbilt.edu/twiki/ bin/view/Main/Power Sample Size, last accessed 16 April 2017). At the 5% significance level, we had 89.5% power to detect an odds ratio of 1.2 with a lower minor allele frequency of 0.167 of rs2233656 in the control subjects.
RESULTS
Characteristics of the participants
Demographic and clinical characteristics of study subjects are summarized in Table 1 . Although an age-matching (5 years) approach was performed, the HT cases showed a slightly higher age of 3.42 years than the controls (P < 0.001). As expected, there were significant differences in systolic BP, diastolic BP, body mass index (BMI), TC, TG, LDL-C, and glucose levels between 2 groups (P < 0.001 for all).
Single locus association analysis for case-control population
The genotypes of all 4 SNPs were in Hardy-Weinberg equilibrium in the control group (P > 0.05). There was no significant difference in the genotypic and allelic frequencies of the 4 SNPs observed between HT cases and controls even after the adjustment for sex, age, BMI, TC, TG, high-density Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; GLU, glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, lowdensity lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
lipoprotein cholesterol, LDL-C, glucose, drinking, and smoking (Table 2) .
Haplotype analysis
The haplotypes of rs238243 and rs2233656, and rs238238 and rs238239 with HT were constructed respectively. The haplotype analysis identified none significant haplotype for HT (Supplementary Table S2 ).
Stratification analysis
Furthermore, the results of stratification analysis by age, gender, smoking, and drinking showed that none of the 4 SNPs was associated with HT even after adjusting covariates (Supplementary Table S3 ).
Quantitative trait analysis for BP
Considering that antihypertensive treatment might have affected the measured BP, we divided the subjects into an antihypertensive-treated group and an untreated group that consisted of untreated hypertensive individuals and controls. The results of GLM analysis showed that no statistical difference in systolic BP and diastolic BP was observed among the different genotypes in either treated or untreated group (P > 0.05) even after adjustment for age, sex, BMI, TC, TG, high-density lipoprotein, LDL, glucose, drinking, and smoking (Supplementary Table S4 ).
Association analysis for incident HT of follow-up study
After an average of 5.01-year follow-up, 29.0% of participants (613) free of HT at baseline developed HT and the incidence density was 65.68 (per 10 3 person-year). Cox regression analysis showed that all 4 SNPs were not associated with incident HT in the follow-up population even after adjustment for sex, age, BMI, TC, TG, high-density lipoprotein cholesterol, LDL-C, T2DM, drinking, and smoking (Table 3 ). Further stratification analysis by age, gender, smoking, and drinking revealed no significant association of the 4 SNPs with HT after adjustment for covariates (Supplementary Table S5 ).
Comparing of plasma profilin1 between HT cases and controls
The results of Mann-Whitney U test showed that HT cases presented higher plasma profilin1 median (P 25 , P 75 ) with 96.93 (11.91, 242.46) ng/ml than that of control subjects [26.68 (1.95, 156.79) ng/ml], Z = −2.528, P = 0.011 (Figure 1 ).
Comparing of plasma profilin1 among different genotypes
The results of Jonckheere-Terpstra test suggested that the profilin1 levels of controls decreased gradually with A to G variation of rs238243 at PFN1 (P = 0.041, Figure 2) , and it dissimilarly tended to increase with the variations of rs238243 in HT cases, whereas the P value failed to reach significance (P = 0.065). The profilin1 levels of HT cases rose gradually with A to G variation of rs238238 at ENO3 (P = 0.004), and it contrarily tended to decrease with the variations of rs238238 despite the borderline P value did not reach significance (P = 0.053). The results of distribution of profilin1 levels among remaining SNPs were listed in Supplementary Table S6 .
DISCUSSION
Vascular remodeling is now considered to be a more complex progress including intima-media thickening, accumulation of matrix substances, and increased media-to-lumen ratio, ultimately leading to the reduced compliance and elevation of BP. 22 Several studies showed that Rho/RockⅡ, mitogen-activated protein (MAP) kinase cascade, extracellular signal-regulated kinase (ERK)1/2, and c-Jun NH2-terminal kinase (JNK) signaling pathway all regulated the remodeling of blood vessels and vascular hypertrophy. [23] [24] [25] [26] PFN1 encodes a small, highly conserved protein that is proposed to be a player in the activation of this hypertrophic signaling pathway. 6,10, 13 Hassona MD, et al. 10 reported that the increased actin polymerization and stress fiber formation via overexpression of profilin1 in the blood vessel medial layer of transgenic mice were found to generate mechanical force and led to vascular hypertrophy and HT. They further elucidated that clear signs of remodeling and vascular hypertrophy were observed in the aorta of profilin1 transgenic mice, while significant increases in the expression of α1 and β1-integrin, Rho-GTPase activity, ROCKII expression, MAP kinase, phosphorylated ERK1/2, and JNK were showed in the mesenteric arteries of profilin1 mice. 13 Moreover, an upregulation of profilin was demonstrated in the established monocrotaline model of experimental rat pulmonary HT both in vivo and in the cultured cell. The result suggested that profilin may contribute to the enhanced invasiveness and growth of smooth muscle cells by intensifying the remodeling of subcortical actin filaments, and lead to the increased vascular resistance and pulmonary HT. 27 In the current study, we examined the associations of 4 SNPs (rs238243, rs2233656, rs238238, and rs238239) with HT and BP variability in a Han Chinese population. Of note, the plasma profilin1 of HT cases was significantly higher than that of controls, which further confirmed the association of profilin1 with HT. Although, there was no significant association between PFN1 polymorphisms and HT as well as BP variability.
Remarkably, the profilin1 levels of controls decreased gradually with A to G variation of rs238243 at PFN1, whereas it dissimilarly tended to increase with the variations of rs238243 in HT cases. The results suggested that variant of rs238243 might be indirectly associated with HT by epigenetic modification regulating profilin1 expression. Rs238243 (A/G) was predicted to be an enhancer located in intron 2 of PFN1 and the functional prediction showed that variation of A to G of rs238243 may affect the binding of the transcription factor C/EBP-α (CCAAT/enhancer element-binding protein), which regulated the expression of PFN1 (http:// alggen.lsi.upc.es/, last accessed 6 May 2017). The profilin1 levels of HT cases increased gradually with A to G variation of rs238238 at ENO3, and it contrarily tended to decrease with the variations of rs238238 in controls. Rs238238 was predicted to be a missense variant at exon region of ENO3 and variation of rs238238 also affect the binding of the transcription factor C/EBP-α. In the same way, the profilin1 varied with the variations of rs238243 and rs238238 in HT cases and control, respectively. These findings coincided with the high linkage disequilibrium value (r 2 = 0.72) between the 2 SNPs. Therefore, further functional research on the variant of rs238243 and 238238 would be warranted.
Certain limitations of the study should be addressed. First, we selected candidate SNPs with the criteria of minor allele frequency ≥0.05 and could have missed the chance of evaluating rare variants at PFN1 for HT. Second, the moderate sample size for measuring plasma profilin1 might be lack of necessary power to confirm the association of profilin1 and incident HT in the follow-up population. In spite of these limitations as above, this study firstly examined the association of PFN1 and ENO3 with HT in a populationbased study with a relative large sample size, and reported a positive association between profilin1 and HT.
In conclusion, our result further confirms the association of profilin1 and HT with population-based evidence and the finding provides the basis for better refining the role of profilin1 in BP control and the prognosis of HT. The profilin1 levels of controls tended to decrease gradually with variation of rs238243 at PFN1 while the profilin1 levels of HT cases tended to increase gradually with variation of rs238238 at ENO3, although the common variants in PFN1 and ENO3 were found to be not associated with HT and BP trait. The results suggested that variant of rs238243 and rs238238 might regulate profilin1 expression by epigenetic modification and indirectly affects the susceptible threshold of HT. Thus, functional research would be helpful to illustrate biological molecular mechanism of BP variability.
SUPPLEMENTARY MATERIAL
Supplementary data are available at American Journal of Hypertension online.
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